Will active surveillance for clinically localized prostate cancer survive in the era of individualized medicine?

Giorgio Gandaglia; Gianluca Giannarini; Nazareno Suardi; Francesco Montorsi; Alberto Briganti

doi:10.1016/j.eururo.2014.04.020

Will active surveillance for clinically localized prostate cancer survive in the era of individualized medicine?

Eur Urol. 2014 Aug;66(2):186-7. doi: 10.1016/j.eururo.2014.04.020. Epub 2014 May 13.

Authors

Giorgio Gandaglia¹, Gianluca Giannarini², Nazareno Suardi¹, Francesco Montorsi¹, Alberto Briganti³

Affiliations

¹ Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
² Department of Urology, University of Bern, Inselspital, Bern, Switzerland.
³ Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. Electronic address: briganti.alberto@hsr.it.

PMID: 24836154
DOI: 10.1016/j.eururo.2014.04.020

Abstract

The challenge for the next few years will be to individualize prostate cancer treatment and to determine whether or not a cancer will be lethal based on molecular characteristics at the time of diagnosis. In this view, the need for active treatment would represent a failure of any conservative approach.

Publication types

Editorial
Comment

MeSH terms

Adenocarcinoma / diagnosis*
Biomarkers, Tumor / blood*
Bone Neoplasms / diagnosis*
Digital Rectal Examination*
Humans
Male
Prostate / pathology*
Prostate-Specific Antigen / blood*
Prostatic Neoplasms / diagnosis*
Soft Tissue Neoplasms / diagnosis*
Watchful Waiting / methods*

Substances

Biomarkers, Tumor
Prostate-Specific Antigen